Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Sold by Verition Fund Management LLC

Verition Fund Management LLC decreased its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 93.5% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,672 shares of the company's stock after selling 52,485 shares during the period. Verition Fund Management LLC's holdings in Prestige Consumer Healthcare were worth $265,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in PBH. Lombard Odier Asset Management USA Corp purchased a new stake in Prestige Consumer Healthcare during the 2nd quarter valued at $550,000. Sequoia Financial Advisors LLC lifted its position in shares of Prestige Consumer Healthcare by 12.9% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 9,824 shares of the company's stock worth $708,000 after purchasing an additional 1,120 shares during the period. Pinnacle Associates Ltd. lifted its position in shares of Prestige Consumer Healthcare by 60.3% in the 3rd quarter. Pinnacle Associates Ltd. now owns 24,630 shares of the company's stock worth $1,776,000 after purchasing an additional 9,269 shares during the period. Ariel Investments LLC lifted its position in shares of Prestige Consumer Healthcare by 10.7% in the 2nd quarter. Ariel Investments LLC now owns 2,835,203 shares of the company's stock worth $195,204,000 after purchasing an additional 274,212 shares during the period. Finally, Citigroup Inc. lifted its position in shares of Prestige Consumer Healthcare by 66.6% in the 3rd quarter. Citigroup Inc. now owns 76,772 shares of the company's stock worth $5,535,000 after purchasing an additional 30,677 shares during the period. Hedge funds and other institutional investors own 99.95% of the company's stock.

Prestige Consumer Healthcare Price Performance

NYSE:PBH traded down $1.28 during trading hours on Friday, hitting $82.30. 241,429 shares of the stock traded hands, compared to its average volume of 251,842. The company has a quick ratio of 2.10, a current ratio of 3.56 and a debt-to-equity ratio of 0.61. Prestige Consumer Healthcare Inc. has a 1 year low of $57.95 and a 1 year high of $86.36. The company has a market cap of $4.07 billion, a price-to-earnings ratio of 20.02, a price-to-earnings-growth ratio of 2.35 and a beta of 0.49. The stock has a 50 day moving average price of $78.12 and a 200 day moving average price of $72.54.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, meeting the consensus estimate of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The business had revenue of $283.79 million for the quarter, compared to the consensus estimate of $282.09 million. During the same quarter in the previous year, the firm earned $1.07 earnings per share. The company's revenue for the quarter was down .9% on a year-over-year basis. Sell-side analysts forecast that Prestige Consumer Healthcare Inc. will post 4.44 EPS for the current fiscal year.

Insider Activity

In other news, EVP Adel Mekhail sold 9,063 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $82.00, for a total transaction of $743,166.00. Following the sale, the executive vice president now owns 18,365 shares in the company, valued at $1,505,930. This trade represents a 33.04 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Ronald M. Lombardi sold 10,875 shares of the business's stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total transaction of $898,275.00. Following the completion of the sale, the chief executive officer now owns 320,952 shares in the company, valued at $26,510,635.20. This represents a 3.28 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 38,810 shares of company stock worth $3,187,300 over the last quarter. Insiders own 1.60% of the company's stock.

Analysts Set New Price Targets

PBH has been the subject of several research analyst reports. DA Davidson reaffirmed a "buy" rating and issued a $95.00 target price on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. Sidoti cut shares of Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 target price for the company. in a research report on Monday, December 9th. StockNews.com cut shares of Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research report on Tuesday, December 10th. Finally, Jefferies Financial Group reiterated a "hold" rating and issued a $76.00 price target (up from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, Prestige Consumer Healthcare currently has an average rating of "Hold" and a consensus target price of $85.25.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.